- 米国企業
- TITAN PHARMACEUTICALS INC
TITAN PHARMACEUTICALS INCTTNP
| 2011年
12月31日 | 2012年
12月31日 | 2013年
12月31日 | 2014年
12月31日 | 2015年
12月31日 | 2016年
12月31日 | 2017年
12月31日 | 2018年
12月31日 | 2019年
12月31日 | 2020年
12月31日 | 2021年
12月31日 | 2022年
12月31日 |
|---|
| Cash and cash equivalents | 5 | 18 | 12 | 15 | 8 | 14 | 8 | 9 | 5 | 5 | 6 | 3 |
|---|
| Restricted cash | - | - | - | - | - | - | 0 | 0 | - | - | 0 | 0 |
|---|
| Receivables | 4 | 5 | 5 | 4 | 4 | 4 | 0 | 2 | 1 | 1 | 0 | 0 |
|---|
| Inventory | - | - | - | - | - | - | - | 1 | 1 | 0 | 0 | 0 |
|---|
| Prepaid expenses and other current assets | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
|---|
| Discontinued operations - current assets | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 |
|---|
| Total current assets | 10 | 23 | 17 | 20 | 12 | 18 | 8 | 13 | 8 | 7 | 7 | 4 |
|---|
| Property and equipment, net | 0 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
|---|
| Other assets | - | - | - | - | - | - | - | - | - | - | 0 | 0 |
|---|
| Operating lease right-of-use asset | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
|---|
| Total assets | 10 | 25 | 18 | 21 | 13 | 19 | 9 | 14 | 10 | 8 | 8 | 4 |
|---|
| Accounts payable | 5 | 4 | 5 | 4 | 4 | 3 | 1 | 2 | 1 | 1 | 1 | 1 |
|---|
| Accrued clinical trials expenses | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
|---|
| Other accrued liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
|---|
| Operating lease liability, current | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
|---|
| Deferred grant revenue | - | - | - | - | - | - | - | - | - | - | 0 | 0 |
|---|
| Discontinued operations - current liabilities | - | - | - | - | - | - | - | - | - | 2 | 1 | 0 |
|---|
| Total current liabilities | 5 | 21 | 11 | 7 | 5 | 5 | 4 | 3 | 4 | 4 | 3 | 3 |
|---|
| Operating lease liability, non-current | - | - | - | - | - | - | - | - | 0 | - | 0 | 0 |
|---|
| Total liabilities | 30 | 48 | 13 | 12 | 6 | 5 | 8 | 7 | 8 | 5 | 3 | 3 |
|---|
| Preferred stock, $0.001 par value per share; 5,000,000 shares authorized, none issued or outstanding at December 31, 2022 and 2021. | - | - | - | - | - | - | - | - | - | - | - | - |
|---|
| Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized 15,016,295 and 9,914,158 shares issued and outstanding at December 31, 2022 and 2021, respectively. | 256 | 266 | 284 | 289 | 298 | 298 | 298 | 0 | 0 | 0 | 0 | 0 |
|---|
| Additional paid-in capital | 18 | 21 | 22 | 22 | 23 | 24 | 26 | 339 | 350 | 371 | 381 | 388 |
|---|
| Accumulated deficit | -295 | -310 | -300 | -303 | -314 | -309 | -323 | -333 | -349 | -367 | -376 | -386 |
|---|
| Total stockholders’ equity | -20 | -23 | 6 | 9 | 7 | 13 | 1 | 7 | 1 | 4 | 5 | 1 |
|---|
| Total liabilities and stockholders’ equity | 10 | 25 | 18 | 21 | 13 | 19 | 9 | 14 | 10 | 8 | 8 | 4 |
|---|